NHS
Cheshire and Merseyside

Area Prescribing Group report

Date: Friday 02 October 2026 **Quorate**: Yes

The items in this report are supported by the area prescribing group (APG) and approval by NHS Cheshire and Merseyside Integrated Care Board (ICB) is detailed below.

All document links provided for any CMAPG recommendations can be found in the Cheshire and Merseyside formulary which will also be updated to reflect these changes.

The legacy Cheshire formulary, and the legacy Pan Mersey APC website and formulary are now closed. Legacy documents are available by using the search function of the Cheshire and Merseyside formulary.

CMAPG governance documents are hosted on the Prescribing section of the NHS Cheshire and Merseyside website.

Please note there may be items that have been considered by APG but not yet approved by NHS Cheshire and Merseyside ICB. Items will be reported in the month that they are approved.

New medicines NICE TAs

Proposal	Notes	Financial implications	Approval
Finerenone for treating heart failure with preserved or mildly reduced ejection fraction **RAG designation:** Green **APG subgroup**: 11 Sep 2026 **APG**: 02 Oct 2026	**Date of NICE TA publication**: 05 Aug 2026 **Approval for implementation**: 90 days **Deadline for implementation**: 03 Nov 2026 Green statement in line with NICE TA1182. Finerenone is a non-steroidal mineralocorticoid receptor antagonist	Estimated 2026-27 financial costs (part year): £31,692.	**MOP**: 15 Oct 2026, clinically supported by MOP group. **ICB Executive Committee:** 02 Nov 2026, approved by ICB Executive Committee.

	(MRA) recommended for treating heart failure with preserved or mildly reduced ejection fraction. It provides an additional treatment option alongside steroidal MRAs spironolactone and eplerenone, which are designated Green on the Cheshire and Merseyside formulary and recommended by NICE NG106 as part of standard heart failure management. Finerenone is significantly more expensive than existing MRAs. It is currently positioned as an additional treatment option within the NICE TA1182 recommendation, but work is ongoing through the Cheshire and Merseyside Cardiac Network to further define where finerenone should be positioned within the treatment pathway in relation to other MRAs.		